Orasis Pharmaceuticals Highlights Early Qlosi Performance One Year After Launch

According to a recent LinkedIn post from Orasis Pharmaceuticals, the company is marking the one-year anniversary of the launch of Qlosi, its eye-care therapy. The post highlights early commercial and clinical indicators, including refill rates that are described as double those seen in established ophthalmic segments for chronic conditions and adverse event rates reportedly in the single digits.

The post also notes that Qlosi’s pupil-selective mechanism has been supported by data from the Bascom Palmer Eye Institute, suggesting a differentiated clinical profile within the presbyopia or broader vision-correction market. For investors, these reported metrics may imply growing product traction, potentially improving revenue visibility and supporting Orasis Pharmaceuticals’ positioning in the competitive ophthalmology space if such trends are sustained over time.